National Research Corp. (NRCIB) Downgraded by Zacks Investment Research to Hold
According to Zacks, “National Research Corporation is a leading provider of ongoing survey-based performance measurement, analysis and tracking services to the healthcare industry. The company addresses the growing need of healthcare providers and payers to measure the care outcomes, specifically satisfaction and health status, of their patients and/or members. The company’s primary types of information services are renewable performance tracking services, custom research and a renewable syndicated service. “
National Research Corp. (NASDAQ:NRCIB) opened at 34.78 on Wednesday. The company has a market capitalization of $842.41 million, a PE ratio of 42.73 and a beta of 0.28. The company has a 50 day moving average of $34.93 and a 200 day moving average of $35.27. National Research Corp. has a 52-week low of $31.88 and a 52-week high of $44.60.
National Research Corp. (NASDAQ:NRCIB) last released its quarterly earnings data on Tuesday, August 2nd. The company reported $0.18 EPS for the quarter, hitting the consensus estimate of $0.18. National Research Corp. had a return on equity of 33.74% and a net margin of 18.75%. On average, equities research analysts forecast that National Research Corp. will post $0.82 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 14th. Stockholders of record on Friday, September 30th will be given a dividend of $0.48 per share. The ex-dividend date is Wednesday, September 28th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 5.52%. National Research Corp.’s payout ratio is currently 408.52%.
In other news, CEO Michael D. Hays sold 3,533 shares of National Research Corp. stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $16.19, for a total transaction of $57,199.27. Following the transaction, the chief executive officer now directly owns 6,467,744 shares of the company’s stock, valued at approximately $104,712,775.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 39.09% of the company’s stock.
An institutional investor recently bought a new position in National Research Corp. stock. Willis Investment Counsel purchased a new position in National Research Corp. (NASDAQ:NRCIB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 13,329 shares of the company’s stock, valued at approximately $442,000. Willis Investment Counsel owned about 0.06% of National Research Corp. at the end of the most recent reporting period. Institutional investors and hedge funds own 2.90% of the company’s stock.
National Research Corp. is a business services company in the Health Care Services industry.
Receive News & Stock Ratings for National Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Corp. and related stocks with our FREE daily email newsletter.